Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib and second-generation Nilotinib (NIL), has pr...
Saved in:
Main Authors: | Hao Zhang (Author), Mingsheng Zhu (Author), Mingzi Li (Author), Duan Ni (Author), Yuanhao Wang (Author), Liping Deng (Author), Kui Du (Author), Shaoyong Lu (Author), Hui Shi (Author), Chen Cai (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021) -
Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017) -
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
by: Congying Gao, et al.
Published: (2023) -
Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance
by: Naoki Okamoto, et al.
Published: (2024) -
Mechanistic Understanding of the Palmitoylation of G<sub>o</sub> Protein in the Allosteric Regulation of Adhesion Receptor GPR97
by: Hao Zhang, et al.
Published: (2022)